BIRT 0377
Alternative Names: BIRT 377Latest Information Update: 15 Dec 2004
At a glance
- Originator Boehringer Ingelheim
- Class Small molecules
- Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 15 Dec 2004 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 01 Jul 2003 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 30 Apr 2001 Preclinical development for Autoimmune disorders in USA (Unknown route)